Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 27, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 27, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 27, 2004
- WORLD NEWS IN BRIEF
September 27, 2004
- GSK to Broadcast Educational Drama on Depression via Web
September 27, 2004
- AdvaMed "Bringing Innovative Med Technology to Patients Worldwide": Mr Collins
September 27, 2004
- Korosho to Request Revision of Package Insert for Iressa
September 27, 2004
- Survey of All Patients Using Remicade Enters 2nd Year: Tanabe
September 27, 2004
- Korosho to Start New Project to Help Development of New Immunosuppression Therapies
September 27, 2004
- Chugai to Drastically Reorganize Marketing System in October
September 27, 2004
- Prefectural Gov'ts Asked to Prepare for Flu Season
September 27, 2004
- Formulation Research Committees of PMAT, OPMA Merge Under Aegis of JPMA
September 27, 2004
- CDFS Task Force to Draft New GL on Use of Blood Products
September 27, 2004
- Strategic Health Care Industry Reform Conference
September 27, 2004
- REGULATORY NEWS IN BRIEF
September 27, 2004
- Modifications of Azwell's, Fukujin's Business Reconstruction Plan Approved
September 27, 2004
- Japanese Healthcare Q&A (11)
September 27, 2004
- MOSS Institute Aims to Make Comeback via EDC Business
September 27, 2004
- 61.2% of JMHA Hospitals Recorded Deficits in FY2003: Survey
September 27, 2004
- BUSINESS NEWS IN BRIEF
September 27, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…